FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,333 | -50.2% | 6,289 | +137.0% | 0.00% | – |
| Q4 2022 | $26,779 | -46.4% | 2,654 | +18.7% | 0.00% | – |
| Q3 2022 | $50,000 | -82.3% | 2,235 | -80.5% | 0.00% | – |
| Q2 2022 | $283,000 | +16.9% | 11,436 | +83.4% | 0.00% | – |
| Q1 2022 | $242,000 | -48.6% | 6,236 | +14.9% | 0.00% | -100.0% |
| Q2 2021 | $471,000 | +592.6% | 5,427 | +220.9% | 0.00% | – |
| Q3 2020 | $68,000 | -71.9% | 1,691 | -76.1% | 0.00% | -100.0% |
| Q2 2020 | $242,000 | -58.6% | 7,064 | -73.2% | 0.00% | -80.0% |
| Q1 2020 | $585,000 | +1047.1% | 26,322 | +915.5% | 0.01% | – |
| Q4 2019 | $51,000 | +1175.0% | 2,592 | +881.8% | 0.00% | – |
| Q3 2019 | $4,000 | -86.7% | 264 | -82.0% | 0.00% | – |
| Q2 2019 | $30,000 | -61.0% | 1,464 | -66.5% | 0.00% | -100.0% |
| Q1 2019 | $77,000 | -22.2% | 4,364 | -43.5% | 0.00% | 0.0% |
| Q4 2018 | $99,000 | -62.5% | 7,725 | -66.9% | 0.00% | -50.0% |
| Q2 2018 | $264,000 | – | 23,312 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |